Jan. 10 at 8:24 AM
$MAIA What if MAIA phase 3 mirrors phase 2 and resists acquaintance an̈d desires legecy considering, company named after daughter. THIO can target 90% of cancers. Plus they can make strategic agreement for capital via financial genius and insider Stan Smith, Phd.
Long-Term Stock Price Projection (2030-2035 Horizon)
In this ultra-bull case, expect phased upside:
Near-Term (2026-2028): Phase 3 readout by late 2026/early 2027 sparks 5-10x rally to
$8.X-16 as approval nears, drawing institutional inflows and partnerships.
Mid-Term (2028-2030): Post-approval commercialization + initial expansions; sales ramp to
$1.X-2B. Market cap hits
$5-10B (P/S 5x), stock
$100-200 (accounting for ~20-30% dilution from funding/options).
Long-Term (2030+): Full SOC status across multiple cancers drives
$5-10B peak sales. At 5-10x multiple, market cap
$25-100B. With ~50M fully diluted shares (minimal dilution via partnerships), stock could reach
$500-2,000. This mirrors Seagen's path but broader applicability.
Overall,
$300-800 feels realistic long-term if THIO truly disrupts 90% of hard-to-treat oncology—turning MAIA into a
$20-40B company. Monitor catalysts like interim Phase 3 data and deal announcements. Bullish if the science holds!
If the above holds true with Bull Case scenario and you invest just a little now.
1. You have created generational wealth
2. THIO will be highlighted in science books 20 years from now making former treatments look barbaric in comparison
3. More importantly, millions of cancer patient lives will be saved
Knowing the risk, I limit my high risk high reward to 8% of portfolio knowingly and accepting I may lose all. Yet, will pray for millions of cancer patients and generations following you and I that success blesses us.
NFA DYOR
